(0.26%) 5 031.33 points
(0.37%) 38 045 points
(0.54%) 15 689 points
(-0.29%) $78.77
(4.45%) $2.02
(-0.06%) $2 309.70
(0.84%) $26.97
(0.74%) $962.00
(0.28%) $0.936
(0.28%) $11.06
(0.33%) $0.801
(-1.38%) $91.98
@ $22.40
发出时间: 13 Feb 2024 @ 22:30
回报率: 15.63%
上一信号: Feb 12 - 22:36
上一信号:
回报率: -3.80 %
Live Chart Being Loaded With Signals
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications...
Stats | |
---|---|
今日成交量 | 49 438.00 |
平均成交量 | 361 357 |
市值 | 707.55M |
EPS | $0 ( 2024-03-13 ) |
下一个收益日期 | ( $-1.540 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.26 |
ATR14 | $0.0890 (0.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-22 | Faga Daniel | Sell | 145 940 | Common Stock |
2024-03-25 | Faga Daniel | Sell | 3 000 | Common Stock |
2024-03-26 | Faga Daniel | Sell | 347 441 | Common Stock |
2024-02-16 | Loumeau Eric J | Sell | 5 000 | Employee Stock Option (right to buy) |
2024-02-16 | Loumeau Eric J | Buy | 5 000 | Common Stock |
INSIDER POWER |
---|
37.31 |
Last 98 transactions |
Buy: 3 215 504 | Sell: 1 263 529 |
音量 相关性
AnaptysBio Inc 相关性 - 货币/商品
AnaptysBio Inc 财务报表
Annual | 2023 |
营收: | $17.16M |
毛利润: | $14.78M (86.15 %) |
EPS: | $-6.08 |
FY | 2023 |
营收: | $17.16M |
毛利润: | $14.78M (86.15 %) |
EPS: | $-6.08 |
FY | 2022 |
营收: | $10.29M |
毛利润: | $7.95M (77.30 %) |
EPS: | $-4.57 |
FY | 2021 |
营收: | $63.18M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.11 |
Financial Reports:
No articles found.
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。